KRAS and malignant colon neoplasm: A recent pooled analysis of seven clinical trials [115] has reported that KRAS exon 2 and BRAFV600E mutations correlate with a shorter time to recurrence (TTR) in patients with surgically removed stage III microsatellite stable (MSS) colon cancer, whereas TTR remains unaffected in patients with microsatellite instability-high (MSI-H) tumors.